: T2 Biosystems’ stock extends losing streak despite FDA approval for anthrax and plague diagnostic test

Shares of T2 Biosystems extended their losing streak to two days Wednesday.

Previous post : Biden administration offers free COVID tests again
Next post : Former Facebook security head warns 2024 election could be ‘overrun’ with AI-created fake content